Michelle Gilson
Stock Analyst at Morgan Stanley
(1.10)
# 3,806
Out of 5,050 analysts
31
Total ratings
32.14%
Success rate
-7.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $5.13 | +289.86% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $73.72 | -59.31% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $10.76 | +57.99% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $197.74 | -0.88% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $32.34 | +39.15% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $22.86 | +232.46% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $51.46 | +76.84% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $5.13
Upside: +289.86%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $73.72
Upside: -59.31%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $10.76
Upside: +57.99%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $197.74
Upside: -0.88%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $32.34
Upside: +39.15%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $22.86
Upside: +232.46%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $51.46
Upside: +76.84%